Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors

Inclusion Criteria: * Patient has provided written informed consent. * Patient meets one of the following criteria: * Already enrolled and on treatment with copanlisib in Bayer-sponsored Study 17067 (CHRONOS-3), OR * Already enrolled and on treatment with copanlisib in an investigator-initiated research (IIR)/institution-sponsored collaborative study (ISCS), OR * Currently on copanlisib treatment prescribed by a healthcare provider. * Patient is deriving an objective favorable response from copanlisib in the opinion of their healthcare provider. * Patient has no suitable alternative treatments available. * Women of childbearing potential and men must agree to use effective contraception when sexually active due to potential embryo-fetal toxicity for 1 month after the last dose. Exclusion Criteria: * Patients who may have developed a disease/condition/toxicity that would conflict with continuing to receive copanlisib treatment. * Patients on treatment with rituximab (R) either alone or in combination with chemotherapy, including an alkylating agent (e.g. bendamustine \[R-B\] or cyclophosphamide, hydroxydoxorubicin, vincristine, prednisone \[R-CHOP\]) for relapsed indolent non-Hodgkin's lymphoma (iNHL).